Results 121 to 130 of about 5,260,545 (402)

Recent advances in the role of polysaccharides in liver diseases: a review

open access: yesFrontiers in Pharmacology
Liver diseases are a serious health problem worldwide, especially with a sustained increase in the burden of it every year. However, drugs commonly used in patients have limited efficacy and serious adverse reactions associated with long-term use ...
Junfeng Wang   +7 more
doaj   +1 more source

Oral bioavailability and drug/carrier particulate systems [PDF]

open access: yes, 2008
The oral route remains the preferred route of administration to ensure patient satisfaction and compliance. However, new chemical entities may exhibit low bioavailability after oral administration because of poor stability within the gastrointestinal ...
A. Wawrezinieck   +3 more
core   +1 more source

An expert consensus for the management of chronic hepatitis B in Asian Americans. [PDF]

open access: yes, 2018
BACKGROUND: Hepatitis B virus (HBV) infection is common with major clinical consequences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which approximates the rates from their countries of origin.
Abbas   +173 more
core   +2 more sources

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

open access: yesMolecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero   +8 more
wiley   +1 more source

Research Progress of Nanomaterials Acting on NK Cells in Tumor Immunotherapy and Imaging

open access: yesBiology
The prognosis for cancer patients has declined dramatically in recent years due to the challenges in treating malignant tumors. Tumor immunotherapy, which includes immune target inhibition and chimeric antigen receptor cell treatment, is currently ...
Yachan Feng   +6 more
doaj   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Advances in drug delivery systems utilizing blood cells and their membrane-derived microvesicles

open access: yesDrug Delivery
The advancement of drug delivery systems (DDSs) in recent decades has demonstrated significant potential in enhancing the efficacy of pharmacological agents.
Andong He   +3 more
doaj   +1 more source

Nanomedicine for the Treatment of Non-Hodgkin Lymphoma [PDF]

open access: yes, 2019
Non-Hodgkin lymphoma, or NHL, is the predominant category of lymphoma. NHL is a type of lymphoid hematopoietic malignancy which approximately 70,000 Americans are diagnosed with annually, with the number of diagnoses growing annually.
Gandhi, B.Pharm, Tanvi
core   +1 more source

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]

open access: yes, 2014
BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari   +55 more
core   +2 more sources

Home - About - Disclaimer - Privacy